GAM Holding’s ImmunityBio IBRX Stock Holding History

GAM Holding’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-54,178	Closed	-$202K	–	245
2022 Q2	$202K	Hold	54,178	–	–	0.01%	243
2022 Q1	$304K	Buy	54,178 +20,939	+63%	+$128K	0.02%	282
2021 Q4	$202K	Hold	33,239	–	–	0.01%	332
2021 Q3	$324K	Hold	33,239	–	–	0.02%	261
2021 Q2	$475K	Buy	+33,239	New	+$549K	0.02%	257

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

GAM Holding's IBRX Position: Q3 2022 in Review

GAM Holding sold out of ImmunityBio (IBRX) in Q3 2022, closing a stake of 54,178 shares — an estimated $202K sold.

GAM Holding first reported a position in IBRX in Q2 2021 and held it in 5 quarters. The position peaked at $475K in Q2 2021. 126 funds tracked by Wall St. Rank hold IBRX as of Q3 2022.

GAM Holding reported no remaining ImmunityBio position as of Q3 2022 after selling out during the quarter.
GAM Holding sold 54,178 ImmunityBio shares in Q3 2022, an estimated $202K.
GAM Holding first reported a position in ImmunityBio in Q2 2021 and held it in 5 quarters.
GAM Holding's ImmunityBio position peaked at $475K in Q2 2021.
126 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2022.

Based on GAM Holding's 13F filing for Q3 2022, filed 19 Oct 2022.